More importantly, exogenous overexpression of cNFIB also enhanced anti-tumor effects of trametinib (a specific MEK inhibitor), which implies its promising potential as a therapeutic molecule for combating ICC metastasis. This evidence concerns the gene MAP2K7 and neoplasm.